Matthew S. Murphy

Partner

Contact

Practice Areas

Intellectual Property

Matt Murphy leverages his prior experience as a research scientist to represent pharmaceutical, life sciences, and other companies in complex patent and trade secret litigation.

Matthew S. Murphy

Partner

Hartford

Contact

Practice Areas

Intellectual Property

Download PDF Download V-Card

Matt Murphy leverages his prior experience as a research scientist to represent pharmaceutical, life sciences, and other companies in complex patent and trade secret litigation.

Recognized among IAM Patent 1000’s “World's Leading Patent Professionals,” Matt combines his litigation prowess and technical background to provide a 360-degree perspective on the legal trends and business challenges clients face. His experience in research and development for leading pharmaceutical and medical device companies makes him particularly adept at understanding the product development process and communicating highly technical information to judges and juries.

In addition to representing pharmaceutical, life sciences, and medical device companies, Matt advises clients in the Fintech, wireless communications, healthcare, and lighting industries. He has driven multiple patent and trade secret litigations with multibillion-dollar claims to successful resolution.

Matt is the training partner for associate lawyers in Axinn’s Intellectual Property Practice Group. His pro bono work includes helping nonprofits, startups, and small businesses secure copyright protection for artistic works. He is a member of the Connecticut Bar Association Intellectual Property Section Executive Committee.

Experience

Representation of a major public corporation in a trade secret and breach of contract litigation involving electronics products in the United States Court for the District of Connecticut.
Representation of a leading manufacturer in patent litigation concerning food products in the United States District Court for the Northern District of Illinois.
Defense of a billion dollar patent litigation involving a generic drug in the United States District Court for the District of New Jersey.

Honors

IAM Patent 1000, World's Leading Patent Professionals (2023 – 2024)
Lawdragon, 500 Leading Litigators in America (2025)
Best Lawyers in America, Litigation – Intellectual Property and Litigation – Patent (2024 – 2025)
Super Lawyers, Rising Stars (2019)

Education

JD – University of Connecticut School of Law (2009)
BS, Chemistry, cum laude – University of Connecticut (2001)

Admissions

Connecticut
New York
U.S. Court of Appeals for the Federal Circuit
U.S. Court of Appeals for the DC Circuit
U.S. District Court District of Connecticut
U.S. District Court District of Columbia

Quotes

A standout IP practitioner in every sense. He is smart and very thorough, and he has an excellent strategic mind that he deploys to find practical and cost-effective solutions to IP issues.

IAM Patent 1000

Axinn proves to have not just the necessary knowledge and skill to handle complex and sophisticated matters, but the depth of experience to anticipate unforeseen hurdles.

Chambers USA

A standout IP practitioner in every sense. He is smart and very thorough, and he has an excellent strategic mind that he deploys to find practical and cost-effective solutions to IP issues.

IAM Patent 1000

A standout IP practitioner in every sense. He is smart and very thorough, and he has an excellent strategic mind that he deploys to find practical and cost-effective solutions to IP issues.

IAM Patent 1000

News & Insights

View all Insights

December 9, 2024

NYC Bar Trade Secrets Symposium 2024: Navigating the Law of Trade Secrets and Restrictive Covenants

On December 9, Axinn partner Matthew Murphy will speak on the "Complex Damages Issues in Trade Secret and Non-Compete Disputes" panel at the New York City Bar Association's Trade Secrets Symposium, being held virtually December 9-10.

Speaking Engagement

Intellectual Property

October 30, 2024

Kisaco Research Pharma and Biotech Patent Litigation 2024

On October 30, Axinn partner Matthew Murphy will speak on "The Global Application of Skinny Labeling and Second Medical Uses" at Kisaco Research's Pharma and Biotech Patent Litigation Conference, being held October 29-30.

Speaking Engagement

Intellectual Property

October 20, 2024

Apportionment of Trade Secret Damages: Will Phillips 66 Ask A Six Hundred Million Dollar Question?

In a trade secret misappropriation action, a complainant is required to prove the amount of its damages with reasonable certainty and that this amount has been caused by the misappropriation. Therefore, the trade secret owner should be prepared to explain how its claimed or awarded damages are sufficiently apportioned to the trade secrets alleged or found to have been misappropriated. Easy to say in principle, harder to execute in real life.

Axinn Viewpoints

Intellectual Property

September 17, 2024

Kisaco Research Second Annual Trade Secret IP Protection & Litigation Summit

On September 17, Axinn partner Matt Murphy will speak on the "Damages in Trade Secret Litigation Cases: How Is the Proportion of Damage Balanced?" panel at Kisaco's Research's Trade Secret IP Protection & Litigation Summit, being held September 17-18 in Boston.

Speaking Engagement

Intellectual Property

August 15, 2024

Axinn Attorneys Named to Best Lawyers 2025

Axinn is pleased to announce that eleven attorneys have been named to the 2025 list of “Best Lawyers in America” and sixteen attorneys have been named to the list of “Ones to Watch.” Two attorneys have been named “Lawyer of the Year” in their individual practice areas. Best Lawyers® compiles their lists of outstanding attorneys by conducting peer-review surveys in which tens of thousands of leading lawyers confidentially evaluate their professional peers.

Awards & Recognitions

Antitrust

June 5, 2024

Axinn and IP Partners Ranked by IAM Patent 1000 2024

Axinn is pleased to announce that IAM Patent 1000 has ranked the firm for California litigation and New York litigation for 2024. The IAM Patent 1000 is commonly regarded as the definitive ‘go-to’ resource for those seeking to identify world-class, private practice patent expertise. When identifying the leading firms, factors such as depth of knowledge, market presence, and the level of work on which they are typically instructed were all taken into account, as well as positive peer and client feedback.

Awards & Recognitions

Intellectual Property

News & Insights

Related People

Matthew J. Becker

Intellectual Property Practice Chair

Matt Becker is the Chair of the Intellectual Property practice and has over 25 years of experience trying and litigating a diverse range of patent infringement and trade secret cases. He has tried numerous high-stakes cases to both courts and juries.

Learn more

Aziz Burgy

Partner

Experienced Hatch-Waxman Patent Litigator

As a first-chair trial attorney for major brand and generic drug companies in over 80 Hatch-Waxman Act cases, Aziz Burgy brings a wealth of experience to pharmaceutical patent litigation. Aziz has been honored among the top 3% of ANDA litigators in Patexia intelligence reports and is consistently recognized by various publications, including IAM Patent 1000, LMG Life Sciences, and Benchmark Litigation. Aziz also advises clients on FDA matters and with product selection to help clients target products for acquisition or development.

Learn more

Brian P. Johnson

Partner

With over 15 years of experience, Brian Johnson is a first chair IP litigation attorney representing clients before the International Trade Commission (ITC) and district courts. He represents clients in litigations involving a wide range of technologies. Brian has had the privilege of representing many of the largest telecommunications companies in the world on many high-stakes competitor disputes. Brian has also argued multiple appeals before the Federal Circuit.

Learn more

Ted Mathias

Partner

Ted Mathias serves as lead counsel in complex patent litigation, often managing cases involving more than 15 patents. He frequently handles matters at the intersection of patent and antitrust law, with a strong focus on advising clients in the pharmaceutical industry.

Learn more